アイスランド -
アイスランド語 -
LYFJASTOFNUN (Icelandic Medicines Agency)
pentavac stungulyfsstofn og dreifa, dreifa
sanofi pasteur* - filamentous haemagglutinin; poliovirus inactivated type 2; poliovirus inactivated type 3; diphtheria toxoid; tetanus toxoid; poliovirus inactivated type 1; pertussis toxoid; haemophilus influenzae type b - stungulyfsstofn og dreifa, dreifa
アイスランド -
アイスランド語 -
LYFJASTOFNUN (Icelandic Medicines Agency)
repevax stungulyf, dreifa áfyllt sprauta
sanofi pasteur* - tetanus toxoid; diphtheria toxoid; pertussis toxoid; filamentous haemagglutinin; pertussis fimbrial agglutinogens (fim) 2 and 3; pertactin; poliovirus (inactivated) type 1 (mahoney strain); poliovirus (inactivated) type 2 (mef-1 strain); poliovirus (inactivated) type 3 (saukett strain) - stungulyf, dreifa - áfyllt sprauta
欧州連合 -
アイスランド語 -
EMA (European Medicines Agency)
vaxneuvance
merck sharp & dohme b.v. - pneumococcal polysaccharide conjugate vaccine (adsorbed) - sýkingar af völdum pneumókokka - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. sjá kafla 4. 4 og 5. 1 til að fá upplýsingar um vernd gegn tilteknum sermigerðum pneumokokkum. the use of vaxneuvance should be in accordance with official recommendations.
アイスランド -
アイスランド語 -
LYFJASTOFNUN (Icelandic Medicines Agency)
vigamox (moxifloxacin alcon) augndropar, lausn 5 mg/ml
novartis healthcare a/s - moxifloxacinum hýdróklóríð - augndropar, lausn - 5 mg/ml
アイスランド -
アイスランド語 -
LYFJASTOFNUN (Icelandic Medicines Agency)
kåvepenin filmuhúðuð tafla 1 g
viatris aps - phenoxymethylpenicillinum kalíum - filmuhúðuð tafla - 1 g
アイスランド -
アイスランド語 -
LYFJASTOFNUN (Icelandic Medicines Agency)
kåvepenin filmuhúðuð tafla 500 mg
viatris aps - phenoxymethylpenicillinum kalíum - filmuhúðuð tafla - 500 mg
アイスランド -
アイスランド語 -
LYFJASTOFNUN (Icelandic Medicines Agency)
kåvepenin filmuhúðuð tafla 800 mg
viatris aps - phenoxymethylpenicillinum kalíum - filmuhúðuð tafla - 800 mg
アイスランド -
アイスランド語 -
LYFJASTOFNUN (Icelandic Medicines Agency)
kåvepenin mixtúrukyrni, dreifa 100 mg/ml
viatris aps - phenoxymethylpenicillinum kalíum - mixtúrukyrni, dreifa - 100 mg/ml
アイスランド -
アイスランド語 -
LYFJASTOFNUN (Icelandic Medicines Agency)
kåvepenin frukt (kåvepenin (mixt. 50 mg/ml)) mixtúrukyrni, dreifa 50 mg/ml
viatris aps - phenoxymethylpenicillinum kalíum - mixtúrukyrni, dreifa - 50 mg/ml
欧州連合 -
アイスランド語 -
EMA (European Medicines Agency)
dengvaxia
sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - fjölmörgum - bóluefni - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 og 4. notkun dengvaxia ætti að vera í samræmi við opinbera tillögur.